In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Large Molecules: Too Late For Big Pharma?

Executive Summary

At a time when the pharmaceutical industry is desperately looking for ways to increase productivity and fatten pipelines, it would only seem sensible for drug companies to maximize their opportunities by creating substantial large molecule capabilities. But even with the renewed interest in monoclonal antibodies, there's little evidence that more than a few major drug companies have made a serious commitment to macromolecule drug discovery and development. Some industry observers contend that companies failing to make such a commitment do so at considerable peril. On the other hand, new technologies may help to make large molecules easier, cheaper, and thus more palatable for drug firms to work with. The question is whether those companies caught up in the small molecule paradigm will seize the opportunity before being left in the dust by those already focusing on macromolecules.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts